Track record · closed signal

Merck & Co. Inc. (MRK) — closed signal from March 18, 2026

Near target Published before the outcome was known, scored automatically when the window closed on June 16, 2026 — +1.5% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$110.41 – $114.35Entry zone — fair-value band

$113.51Published — price the day we called it

$123.97Target — the price the thesis aimed for

$123.11Peak — highest point inside the window, not a realized return

$115.17Window close — end-of-window price, context only

What happened

Near target

Came within reach: 85% of the predicted growth at its peak, just short of the target.

At window close

+1.5%

realized, from the publication price to the last close inside the window

Peak gain

+8.5%

peak, from the publication price — not a realized return

S&P 500, same window

+13.8%

SPY over the identical days, dividend-adjusted

Window close

$115.17

last close inside the window, ended June 16, 2026

Peak price

$123.11

peak on April 9, 2026 — not a realized return

Days to target

—

The thesis — published March 18, 2026

Predicted growth

+10%

over the measurement window

Target price

$123.97

the price the thesis aimed for

Entry zone

$110.41 – $114.35

the fair-value band we waited for

Price at publication

$113.51

published March 18, 2026

Confidence

76%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is being considered as a short-term defensive pick because it makes steady cash and has strong products that last. New data about Gardasil supports confidence in one of its main growth drivers. This is more about a safe rebound and protecting capital than chasing a fast big gain, useful when markets feel uneven.

Primary drivers

New Gardasil data makes the vaccine business look more reliable
Pharma cash flow is steady, which helps in shaky markets
Shares are positioned near a lower-price entry after weakness
Regular earnings make big losses less likely

How it played out

MRK: rose 8.5% but missed the target

Lyra published MRK as a short-term defensive rebound from 113.51, with expected growth of 10%. The thesis pointed to new Gardasil data, steady pharmaceutical cash flow, an entry after weakness, and regular earnings as support against large losses.

During the window, MRK reached a peak of 123.11 on April 9, an 8.5% gain. It stayed below the 123.97 target and never reached it. The shares ended the window at 115.17. The defensive rebound partly played out, but the published 10% objective was missed.

What happened during the window

On April 30, Merck reported first-quarter worldwide sales of $16.3 billion, up 5%. On May 5, the company completed its acquisition of Terns Pharmaceuticals.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals